Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data

Tarun Bhagnani, Jian J. Zhu, David Robert R. Freyer, Kristen M. O'Dwyer, Michael E. Roth, Julie A. Wolfson, Qian Meng, Rui Sammi Tang, Robert G. Paglia

Blood (2022) 140 (Supplement 1): 2190–2192.

https://doi.org/10.1182/blood-2022-162681

Published: 2022

Journal Articles

Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study

Wendy Stock, Jae H Park, Ashkan Emadi, Maher Abdul-Hay, Ryan D. Cassaday, Vinod A. Pullarkat, Jonathan Webster, Shuchi S. Pandya, Mark J Mogul, Yelena Shvenke, Jian J Zhu, Adrien Tessier, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2021-149463

Published: 2021

Journal Articles

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background

Mianmian Yin, Yang Jo Chung, R. Coleman Lindsley, Robert L. Walker, Yuelin J. Zhu, Benjamin L. Ebert, Paul S. Meltzer, Peter D. Aplan

Blood (2019) 133 (24): 2610–2614.

https://doi.org/10.1182/blood.2018864173

Published: 2019

Journal Articles

Identifying Mechanisms of Glucocorticoid Resistance in Relapsed Pediatric T-ALL

Justine E. Roderick, PhD, Kayleigh M Gallagher, BS, Katherine M Tang, BS, Olivia Kugler-Umana, BS, Lihua J Zhu, PhD, Michael R Green, MD PhD, Michelle Kelliher, PhD

Blood (2016) 128 (22): 2769.

https://doi.org/10.1182/blood.V128.22.2769.2769

Published: 2016

Journal Articles

Co-Expression of NUP98-HOXD13 and Mutant IDH2 Triggers an Early T-Cell Precursor-like Leukemia in Mice

Liat Goldberg, PhD, Rachel M Pierce, Masahiro Onozawa, MD PhD, Robert L Walker, Yeulin J Zhu, Paul S Meltzer, MD PhD, Peter D. Aplan, MD

Blood (2015) 126 (23): 904.

https://doi.org/10.1182/blood.V126.23.904.904

Published: 2015

Journal Articles

Spontaneous Mutations of Bcor and Jak1/2 genes Lead to an Aggressive Leukemia of B-1 Progenitor B Cells

Sheryl M Gough, PhD BSc, Liat Goldberg, PhD, Marbin Pineda, MS, Robert L Walker, BSc, Yuelin J Zhu, MD MSc, Sven Bilke, PhD, Paul S Meltzer, MD PhD, Peter D Aplan, MD

Blood (2014) 124 (21): 3573.

https://doi.org/10.1182/blood.V124.21.3573.3573

Published: 2014

Journal Articles

PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia

Leyuan Ma, Yi Shan, Robert Bai, Liting Xue, Christopher A. Eide, Jianhong Ou, Lihua J. Zhu, Lloyd Hutchinson, PhD, Jan Cerny, MD PhD, H. Jean Khoury, MD, Zhi Sheng, Brian J. Druker, Shaoguang Li, MD PhD, Michael Green

Blood (2014) 124 (21): 1790.

https://doi.org/10.1182/blood.V124.21.1790.1790

Published: 2014

Journal Articles

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, MD, Martha Wadleigh, MD, John F. Seymour, MD, PhD, Andrew W. Roberts, MD, PhD, Luen Bik To, Huan J. Zhu, MD, PhD, Ruben A. Mesa, MD

Blood (2011) 118 (21): 282.

https://doi.org/10.1182/blood.V118.21.282.282

Published: 2011

Journal Articles

BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription

Zhi Sheng, Leyuan Ma, Jiaoyuan E. Sun, Lihua J. Zhu, Michael R. Green

Blood (2011) 118 (10): 2840–2848.

https://doi.org/10.1182/blood-2010-12-322537

Published: 2011

Includes: Supplemental data

Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD

Blood (2009) 114 (22): 3905.

https://doi.org/10.1182/blood.V114.22.3905.3905

Published: 2009

Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD

Blood (2009) 114 (22): 588.

https://doi.org/10.1182/blood.V114.22.588.588

Published: 2009

Journal Articles

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Blood (2006) 108 (11): 3580.

https://doi.org/10.1182/blood.V108.11.3580.3580

Published: 2006

Journal Articles

Clinical and Experimental Study in 21 Cases of Acute Leukemia with Trisomy 4.

Jin L. Pan, MD, Yong Q. Xue, MD, Hui Y. Qiu, PhD, Yong J. Zhu, PhD, Ya F. Wu, MD, Yong Wang, MD, Juan Shen, MD

Blood (2006) 108 (11): 4277.

https://doi.org/10.1182/blood.V108.11.4277.4277

Published: 2006

Journal Articles

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins

GQ Chen, J Zhu, XG Shi, JH Ni, HJ Zhong, GY Si, XL Jin, W Tang, XS Li, SM Xong, ZX Shen, GL Sun, J Ma, P Zhang, TD Zhang, C Gazin, T Naoe, SJ Chen, ZY Wang, Z Chen

Blood (1996) 88 (3): 1052–1061.

https://doi.org/10.1182/blood.V88.3.1052.1052

Published: 1996

Journal Articles

Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines

J Zhu, PM Nabissa, B Hoffman, DA Liebermann, SK Shore

Blood (1996) 87 (10): 4368–4375.

https://doi.org/10.1182/blood.V87.10.4368.bloodjournal87104368

Published: 1996

Journal Articles

Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice

SY Zhang, J Zhu, GQ Chen, XX Du, LJ Lu, Z Zhang, HJ Zhong, HR Chen, ZY Wang, R Berger, M Lanotte, S Waxman, Z Chen, SJ Chen

Blood (1996) 87 (8): 3404–3409.

https://doi.org/10.1182/blood.V87.8.3404.bloodjournal8783404

Published: 1996

NARROW

Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data

Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background

Identifying Mechanisms of Glucocorticoid Resistance in Relapsed Pediatric T-ALL

Co-Expression of NUP98-HOXD13 and Mutant IDH2 Triggers an Early T-Cell Precursor-like Leukemia in Mice

Spontaneous Mutations of Bcor and Jak1/2 genes Lead to an Aggressive Leukemia of B-1 Progenitor B Cells

PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Clinical and Experimental Study in 21 Cases of Acute Leukemia with Trisomy 4.

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins

Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines

Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only